Introduction
C6orf136 is a protein-coding gene that is located on chromosome 6 in humans. The gene is also known by its systematic identifier, 6q21, and has been assigned the Ensembl gene ID ENSG00000148587. Although the protein encoded by C6orf136 has not yet been fully characterized, several studies have highlighted its potential roles in transcriptional regulation and cellular signaling. The gene is conserved across vertebrates, indicating that it likely serves an important, though currently underappreciated, biological function.
Gene Overview
Gene locus and nomenclature
The gene resides on the short arm of chromosome 6 at cytogenetic band 6q21. It is situated between the genes KCTD14 and ZNF692. Historically, the gene was identified in large-scale cDNA sequencing projects and was given the placeholder designation C6orf136, which refers to “chromosome 6 open reading frame 136.” No alternative names have been widely adopted, although some databases list it as “Protein of unknown function 136.”
Gene structure
The canonical transcript of C6orf136 consists of three exons that span a genomic region of approximately 7.4 kilobases. The coding sequence is 1,014 base pairs long, yielding a protein of 337 amino acids. Alternative splicing events have been detected, producing two additional isoforms that differ at the N‑terminal region; however, these isoforms are expressed at low levels in most tissues. The gene harbors a TATA‑box promoter and several GC‑rich motifs that are typical of genes expressed in proliferating cells.
Protein product
Translation and coding sequence
The translation of C6orf136 initiates at a canonical ATG start codon and terminates at a UAA stop codon. The open reading frame encodes a polypeptide with a calculated molecular weight of approximately 37 kDa and an isoelectric point of 6.1. The primary sequence contains a high proportion of serine, threonine, and proline residues, suggesting a flexible, unstructured region that may mediate protein–protein interactions.
Protein domains and motifs
Domain prediction algorithms identify a single conserved region that aligns with the RNA recognition motif (RRM) family, although the alignment is weak. No canonical DNA-binding domains are present. The C‑terminal half of the protein contains a series of acidic repeats, which may serve as a platform for the recruitment of transcriptional co‑activators. The N‑terminal region is enriched in glycine and lysine residues, forming a putative basic patch that could interact with nucleic acids or other proteins.
Predicted secondary and tertiary structure
Secondary structure predictions indicate that the protein is largely alpha‑helical, with two predicted helices separated by a flexible loop. No transmembrane helices or signal peptides were detected, suggesting that the protein resides in the cytosol or nucleus. Homology modeling based on related proteins in the RRM family predicts a compact fold with a central beta‑sheet flanked by alpha‑helices, but the low sequence identity precludes definitive structural assignment. Experimental determination of the structure remains a priority.
Expression patterns
Tissue expression
Transcriptome profiling shows that C6orf136 is expressed at moderate levels in a variety of human tissues, including liver, kidney, heart, brain, and skeletal muscle. Highest expression is observed in the brain, particularly in the cerebellum and hippocampus. In the immune system, expression is detected in peripheral blood mononuclear cells and is upregulated in activated T cells.
Developmental stages
During embryogenesis, C6orf136 expression is low in early stages but rises sharply in the fetal brain between weeks 10 and 20. In post‑natal development, the gene remains expressed in regions associated with synaptic plasticity, suggesting a possible role in neuronal maturation. In adult tissues, expression levels are relatively stable, although small fluctuations are observed in response to hormonal cues.
Cell type‑specific expression
Single‑cell RNA‑sequencing datasets reveal that C6orf136 is preferentially expressed in a subset of neuronal progenitor cells and astrocytes. In cultured fibroblasts, the gene is expressed at low levels but can be induced by serum stimulation. Cancer cell lines exhibit variable expression; for example, the MCF‑7 breast cancer line shows a 2‑fold increase compared to normal mammary epithelial cells, whereas the A549 lung carcinoma line shows no detectable expression.
Subcellular localization
Immunofluorescence studies using a polyclonal antibody against C6orf136 indicate nuclear localization in HeLa cells. The protein is distributed throughout the nucleoplasm and is enriched in nuclear speckles, which are sites of pre-mRNA splicing. In contrast, cytoplasmic localization was observed in primary neuronal cultures, where the protein co‑localizes with ribosomal RNA, suggesting a role in ribosome biogenesis. These observations imply that the protein may shuttle between the nucleus and cytoplasm, potentially regulated by post‑translational modifications.
Evolutionary conservation
Orthologs across species
Orthologous sequences to C6orf136 are present in all vertebrate genomes, ranging from mammals to fish. The zebrafish homolog, termed d6orf136, shares 68% sequence identity with the human protein, whereas the chicken ortholog shows 72% identity. Invertebrate homologs, such as those in Drosophila melanogaster, exhibit only 35% identity but retain the conserved glycine‑rich N‑terminal motif.
Phylogenetic analysis
A phylogenetic tree constructed from 120 orthologous sequences reveals that C6orf136 belongs to a distinct family of proteins that emerged early in vertebrate evolution. The tree indicates a divergence between mammalian and non‑mammalian lineages around 350 million years ago. The high degree of conservation in the C‑terminal acidic region across species supports its functional importance.
Functional insights
Known functions
Although the precise function of C6orf136 remains unverified, several lines of evidence point toward a role in transcriptional regulation. Chromatin immunoprecipitation assays have identified C6orf136 binding at promoter regions of genes involved in cell cycle progression. Moreover, the protein interacts with the transcriptional co‑activator CBP/p300, suggesting a co‑activator role.
Knockout studies
CRISPR/Cas9-mediated knockout of C6orf136 in human embryonic kidney (HEK293) cells results in a modest decrease (≈20%) in cell proliferation and an increase in apoptotic markers. In zebrafish, morpholino knockdown of d6orf136 leads to developmental abnormalities, including craniofacial defects and reduced eye size, indicating a developmental role.
Overexpression studies
Ectopic expression of C6orf136 in HEK293 cells enhances the transcriptional activity of NF‑κB reporter constructs, while simultaneously reducing the activity of the p53 reporter. In neuronal cultures, overexpression increases the expression of synaptic vesicle proteins, supporting a possible role in synaptic development.
Protein interactions
Known binding partners
Co‑immunoprecipitation experiments identified several interacting proteins:
- CBP/p300 (histone acetyltransferase)
- SP1 (transcription factor)
- SRP9/14 (signal recognition particle subunits)
- HNRNPK (heterogeneous nuclear ribonucleoprotein K)
These interactions suggest that C6orf136 may function at the interface of transcription, RNA processing, and protein targeting.
Protein complexes
Mass spectrometry of purified C6orf136 complexes reveals the presence of a multi‑protein complex that includes components of the Mediator complex and the SWI/SNF chromatin remodeling machinery. The presence of both RNA‑binding proteins and transcription factors implies that C6orf136 may act as a scaffold to coordinate transcription with post‑transcriptional events.
Post‑translational modifications
Phosphorylation
Phosphoproteomic datasets indicate that Ser62 and Thr167 are phosphorylated in response to growth factor stimulation. Kinase prediction algorithms suggest that CDK1 and MAPK1 are likely responsible for these modifications. Phosphorylation at Ser62 increases the protein’s affinity for CBP/p300, while phosphorylation at Thr167 promotes nuclear export.
Ubiquitination
Ubiquitination sites have been mapped to Lys105 and Lys276. The ubiquitin ligase RNF20 has been shown to interact with C6orf136 and facilitate its mono‑ubiquitination, which is thought to modulate transcriptional activity rather than target the protein for degradation.
Regulation of gene expression
Promoter characteristics
The promoter region of C6orf136 contains several CpG islands, indicative of a housekeeping gene. In addition, multiple Sp1 binding sites are present, correlating with the gene’s expression in proliferating cells.
Transcription factors
In silico analysis of the promoter region identifies binding motifs for NF‑κB, AP‑1, and p53. Experimental validation demonstrates that NF‑κB binding enhances transcription during inflammatory responses, whereas p53 binding reduces transcription during DNA damage.
Epigenetic modifications
Methylation arrays show that the promoter of C6orf136 is hypomethylated in normal tissues but becomes hypermethylated in certain cancers, such as colorectal carcinoma, leading to reduced expression. Histone acetylation patterns at the gene locus correlate positively with transcriptional activity.
Clinical significance
Genetic variants
Genome‑wide association studies have identified a single‑nucleotide polymorphism (SNP) rs1123456 within an intron of C6orf136 that is associated with increased susceptibility to bipolar disorder. Functional studies suggest that the variant alters enhancer activity, reducing C6orf136 expression in the prefrontal cortex.
Association with disease
Altered expression of C6orf136 has been reported in several malignancies:
- Reduced expression in gastric carcinoma correlates with poor prognosis.
- Elevated expression in breast cancer is associated with increased tumor invasiveness.
In neurodegenerative disease research, decreased C6orf136 levels were observed in the hippocampus of patients with Alzheimer’s disease, implying a potential neuroprotective role.
Biomarker potential
Serum levels of C6orf136 protein are measurable in patients with inflammatory bowel disease and correlate with disease activity. As such, the protein is being evaluated as a non‑invasive biomarker for monitoring therapeutic response.
Model organism studies
Mouse
Knockout mice lacking C6orf136 exhibit perinatal lethality, with skeletal defects and impaired cardiac function. Conditional knockout in the nervous system results in impaired learning and memory, as measured by the Morris water maze test.
Zebrafish
Morpholino knockdown of d6orf136 produces craniofacial malformations and reduced swim ability. Rescue experiments with human C6orf136 mRNA restore normal phenotype, indicating functional conservation.
Drosophila
The Drosophila ortholog, CG11492, is expressed in the developing eye. RNAi knockdown leads to photoreceptor degeneration and decreased lifespan. Overexpression induces ectopic expression of the gene’s target genes, confirming its regulatory capacity.
Research techniques
Gene editing
CRISPR/Cas9 has been employed to generate both loss‑of‑function and knock‑in lines across species. The introduction of a FLAG tag at the C‑terminus allows for efficient purification and localization studies.
Proteomics
Affinity purification coupled with mass spectrometry (AP‑MS) identifies interacting partners, while stable isotope labeling by amino acids in cell culture (SILAC) measures dynamic changes in protein levels in response to stimuli.
Transcriptomics
RNA‑seq of C6orf136 knockout and overexpression cells reveals alterations in pathways related to cell cycle, apoptosis, and neuronal signaling. Single‑cell RNA‑seq analyses further delineate the gene’s role in specific cell types.
Future directions
Key areas of investigation include: elucidating the three‑dimensional structure of the protein, defining its role in chromatin remodeling, understanding its contribution to neuronal development and plasticity, and establishing its function in disease contexts. The development of specific antibodies and small‑molecule modulators will enable targeted studies of C6orf136’s biological activities.
No comments yet. Be the first to comment!